Pimozide - Generic Drug Details

What are the generic drug sources for pimozide and what is the scope of freedom to operate?

Pimozide is the generic ingredient in two branded drugs marketed by Teva and Endo Operations, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for pimozide. One supplier is listed for this compound.

Summary for pimozide

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	21
Patent Applications:	6,476
Drug Prices:	Drug price trends for pimozide
What excipients (inactive ingredients) are in pimozide?	pimozide excipients list
DailyMed Link:	pimozide at DailyMed

See drug prices for pimozide

Recent Clinical Trials for pimozide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1
Applied Biology, Inc.	N/A

See all pimozide clinical trials

Pharmacology for pimozide

Drug Class

Typical Antipsychotic

Medical Subject Heading (MeSH) Categories for pimozide

Anti-Dyskinesia Agents

Antipsychotic Agents

Dopamine Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for pimozide

N05AG	Diphenylbutylpiperidine derivatives
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for pimozide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Operations	PIMOZIDE	pimozide	TABLET;ORAL	204521-002	Sep 28, 2015		RX	No	Yes
Teva	ORAP	pimozide	TABLET;ORAL	017473-003	Aug 27, 1997		DISCN	Yes	No
Endo Operations	PIMOZIDE	pimozide	TABLET;ORAL	204521-001	Sep 28, 2015		RX	No	No

Pimozide Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Pimozide

Introduction to Pimozide

Pimozide is an antipsychotic medication primarily used to treat symptoms of schizophrenia, Tourette syndrome, and other psychiatric disorders. It works by blocking the brain's dopamine receptors, thereby reducing the symptoms associated with these conditions.

Market Size and Projections

The global pimozide market has been valued at USD 120 million in 2023 and is projected to reach USD 207.9 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 6.5% from 2024 to 2031[1].

Segmentation of the Pimozide Market

The market is segmented based on several key factors:

Type

• Pimozide tablets
• Pimozide oral solution
• Pimozide injections

Each of these forms has its own market share and growth trajectory, with tablets being the most commonly used form due to their ease of administration and patient compliance[1].

Application

• Schizophrenia
• Tourette syndrome
• Psychosis
• Delusional disorder

The demand for pimozide is driven significantly by the prevalence of these psychiatric conditions. Schizophrenia and Tourette syndrome are among the primary applications, given the drug's efficacy in managing their symptoms[1].

Geographical Regions

• North America
• Europe
• Asia-Pacific
• South America
• Middle-East and Africa

The market growth varies across these regions, influenced by factors such as healthcare infrastructure, awareness of mental health issues, and regulatory environments[1].

Driving Factors of the Pimozide Market

Several factors are propelling the growth of the pimozide market:

Increasing Mental Health Problems

The rising incidence of psychiatric diseases, including schizophrenia and Tourette syndrome, is a significant driver. As mental health awareness increases, so does the demand for effective treatments like pimozide[1][4].

Advances in Diagnostic Capabilities

Improvements in diagnostic technologies and methodologies have led to better identification and treatment of mental health disorders, contributing to the market's expansion[1].

Clinical Recommendations and Regulatory Approval

Clinical guidelines and regulatory approvals supporting the use of pimozide for specific psychiatric conditions enhance its market acceptance and usage[1].

Patient Advocacy and Healthcare Spending

Patient advocacy programs and increasing global healthcare spending on mental health services further boost the market for pimozide[1].

Competitive Landscape

The pimozide market is characterized by a competitive landscape involving several key players:

• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Novartis AG
• Zydus Cadila
• Glenmark Pharmaceuticals Ltd.
• Cipla Ltd.
• Jubilant Life Sciences Ltd.
• Mylan N.V.
• Torrent Pharmaceuticals Ltd.
• Alembic Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Sandoz International GmbH (Novartis)
• Actavis Pharma inc. (Teva Pharmaceutical Industries Ltd.)
• Apotex Inc.
• Gedeon Richter Plc.
• Intas Pharmaceuticals Ltd.
• Janssen Pharmaceuticals inc.[1]

These companies are profiled based on their product offerings, market entry year, and other market-related factors, providing a comprehensive view of the competitive dynamics.

Porter’s Five Forces Analysis

The market report includes a Porter’s Five Forces analysis, which examines:

• Buyers' bargaining power
• Suppliers' bargaining power
• Threat of new entrants
• Threat of substitutes
• Degree of competition

This analysis helps in understanding the market dynamics and the competitive forces at play[1].

Clinical Use and Outcomes

Pimozide is widely used in clinical settings for managing symptoms of schizophrenia and Tourette syndrome. For instance, in the VA healthcare system, 71.3% of individuals with schizophrenia filled one or more prescriptions for oral antipsychotic medications, with pimozide being one of the options[2].

Financial Impact and Healthcare Costs

The financial burden associated with treating psychiatric disorders is significant. Effective treatment with medications like pimozide can reduce long-term healthcare costs by minimizing hospitalizations and improving patient outcomes. For example, early intervention and treatment can lead to reduced financial burdens on both military and veteran healthcare systems[2].

Market Growth Projections

The global pimozide tablet market is expected to reach USD 2195.5 million by 2029, exhibiting a CAGR of 6.3% from 2024 to 2029. This growth is driven by increasing mental health problems and rising awareness of psychological disorders[4].

Challenges and Opportunities

While the market for pimozide is growing, there are challenges such as the threat of new entrants and substitutes. However, ongoing research into new therapeutic applications and formulations presents opportunities for market expansion.

Key Takeaways

• The pimozide market is projected to grow significantly, driven by increasing mental health issues and advances in diagnostic capabilities.
• The market is segmented by type, application, and geographical regions.
• Key players in the market include major pharmaceutical companies.
• Clinical recommendations and regulatory approvals support the market growth.
• Effective treatment with pimozide can reduce healthcare costs and improve patient outcomes.

Frequently Asked Questions

Q: What is the projected market size of the pimozide market by 2031? A: The pimozide market is expected to reach USD 207.9 million by 2031[1].

Q: What is the CAGR of the pimozide market from 2024 to 2031? A: The market is expected to grow at a CAGR of 6.5% from 2024 to 2031[1].

Q: Which are the primary applications of pimozide? A: The primary applications include schizophrenia, Tourette syndrome, psychosis, and delusional disorder[1].

Q: Who are the key players in the pimozide market? A: Key players include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., and others[1].

Q: What factors drive the growth of the pimozide market? A: Increasing mental health problems, advances in diagnostic capabilities, clinical recommendations, and regulatory approvals are among the key drivers[1][4].

Sources Cited

1. Marketresearchintellect, "Global Pimozide Market Size and Forecast".
2. VA/DoD Clinical Practice Guideline, "Management of First-Episode Psychosis and Schizophrenia".
3. Altus Market Research, "Global Pimozide Market 2023 Analysis by Type, Industrial Vertical".
4. Business Research Insights, "Pimozide Tablet Market Share | 2024 To 2032".